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RhoGEFlogy protein family members were implicated early on as being involved in
regulating cytoskeletal remodeling pathways, as formin protein mutations in Drosophila and yeast lead to
obvious actin cytoskeleton defects. The discovery that these proteins associated directly with small Rho
family GTPases conﬁrmed these results and greatly enhanced our understanding of their function. The
mammalian diaphanous-related formins (DRFs) were subsequently recognized as being involved in
activation of serum response factor (SRF), tying formins to transcriptional regulation. In the past few years,
much progress has been made in demonstrating how DRFs act as both downstream effectors and upstream
modulators of Rho GTPase signaling. These functions are important for regulation of both actin and
microtubule cytoskeletal structures, and affect cellular processes such as the establishment of polarity,
vesicle movement, and focal adhesion remodeling. The connection of DRFs to the SH3 domain-containing
protein, Src, has also been described as being important to several basic cellular functions. While still
unresolved, extensive work has been carried out on how DRFs mediate SRF activation, and the importance of
this to the regulation of cytoskeletal structure. This review will focus on the role of formins in cytoplasmic
signal transduction pathways and the downstream effects on the regulation of gene expression.
© 2008 Elsevier B.V. All rights reserved.1. Introduction
Dynamic reorganization of the cytoskeleton is critical for diverse
processes such as organelle positioning, cell movement, vesicle forma-
tion and trafﬁcking, cell division, and for almost any other dynamic
cellular process that has been visualized under a microscope [1–4].
Along with tension generated by simple ﬁlaments coupled to cellular
components such as myosin and adhesion proteins, the direct regulation
of cytoskeletal dynamics provides a driving force for movement within
cells. Formin family proteins act as regulators of cytoskeletal organiza-
tion both directly via actin interactions, and indirectly via multiple
cytoskeletal-associated regulatory proteins. These direct and indirect
effects of formin activity control how cytoskeletal driven functions are
carried out in multiple eukaryotic cells types.
Formins act as effector proteins downstream of signaling inputs
that are well established as triggers for cell movement and shape
change. In the absence of signals that lead to cytoskeletal reorganiza-
tion, DRFs remain inactive and typically localize diffusely in theDAAM, disheveled-associated
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ll rights reserved.cytoplasm [5–7]. Following activation of the small Rho GTPases, Rho,
Rac, Cdc42, or Rif, DRFs become activated. Formins have also been
demonstrated to signal through SH3 domain-containing proteins,
including Src kinase [8,9]. Src regulates diverse processes such as
cellular differentiation, migration, and oncogenesis. Beyond being
coupled to the regulation of cytoskeletal ﬁlaments via signaling
components in the cytoplasm, formins are involved in the activation of
SRF in the nucleus [8,10–14]. This role in SRF activation results in
changes to the expression levels of multiple cytoskeletal-related
proteins. We will start with a brief description of how Rho GTPases
affect cytoskeletal remodeling, and discuss how formins act both as
downstream effectors of the Rho GTPases as well as modulators that
act upstream to either potentiate or terminate Rho GTPase signaling.
The involvement of formins in signaling through SH3 domain
containing proteins, and in particular, Src, will then be discussed.
Finally, we will provide an overview of the role of SRF activation in
cytoskeletal regulation, and the relative importance of formin proteins
in regulating this activation. From each of these examples, it is clear
that formins provide an important regulatory link coupling morpho-
logical change to downstream signaling outputs, as well as mediating
adaptive responses through regulation of gene expression which
govern subsequent cellular behavior.
2. Small GTPases regulate cellular morphology
Early work on the Ras oncoprotein and related small GTPases
demonstrated their importance in controlling cell cycle regulation and
Fig. 1. Domain structures of the mammalian GTPase binding domain-containing
formins. Representative formin structures are shown for mDia1, FRL1, DAAM1 and
FHOD1. Numbering for mDia1 indicates the approximate delineations of the indicated
domains. GBD = GTPase binding domain, DID = diaphanous inhibitory domain, DD =
dimerization domain, CC = coiled coil region, FH1 = formin homology domain 1, FH2
= formin homology domain 2, DAD = diaphanous autoregulatory domain. Self-
association via the DID/DAD interaction is indicated with an arrow for mDia1. These
formins are activated by the binding of Rho family GTPases to the GBD, which interrupts
the DID/DAD interaction. The DD/CC region mediates N-terminal homo-dimerization
and Rho-independent membrane targeting of the protein. The FH1 region interacts with
proﬁlin and SH3 domain-containing proteins. The FH2 region mediates actin ﬁlament
nucleation and homo-dimerization. The exact position of the FHOD1 GBD has not been
mapped. For the domain structures of other formins, refer to [25].
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mutant (RhoV14) demonstrated the potency of Rho in inducing actin
stress ﬁber and focal adhesion formation [16,17]. A similar constitu-
tively active Rac mutant (RacV12) demonstrated its role in membrane
rufﬂe formation and increased F-actin formation [18]. This work has
identiﬁed Rho GTPases (Rho, Rac, Cdc42) as being major triggers forFig. 2. Feedback and cross-talk in DRF-mediated signaling. An overview of signaling events d
shown. Activation of Rho (e.g. LARG) or Rac (e.g. Tiam) GEFs triggers the exchange of GDP fo
FHOD1. Formin activation results in increased formation of actin ﬁlament based structures (r
ROCK, which inhibits a myosin light chain phosphatase (MLCP), resulting in the incorporatio
with mDia and Src at the endosomal (Endo) membrane, which regulate actin ﬁlament form
membrane and localizes at the sites of integrin-based focal adhesions. mDia signaling, possibl
attachment. ECM — extracellular matrix. See the text for more details.inducing actin cytoskeleton remodeling along with affecting other
determinants of cellular morphology. Rho GTPases have since been
demonstrated to be involved in establishing cell polarity, regulation of
cell motility, vesicle secretion, and cell proliferation control, among
other cellular events [19–21]. Tissue-speciﬁc expression, degradation,
interactions with modulatory proteins, regulated localization to
various subcellular compartments, and regulation by various Rho
GEFs and GAPs downstream of extracellular stimuli all play roles in the
regulation of where and when the Rho GTPases will become active
[19,20].
The interactions of the yeast formin Bni1 with the Rho GTPases
Rho1p and Cdc42p were the ﬁrst demonstrations of the regulation of
formin activity by Rho GTPases [22,23]. In budding yeast, Bni1 is
responsible for the formation of actin cables, and is involved in
polarized growth into the bud [24]. The mammalian formin mDia1
was similarly demonstrated to interact with Rho at the plasma
membrane and act as its downstream effector [6]. In vertebrates, a
variety of Rho GTPases are now known to interact with the GTPase
binding domains of DRFs. At least three types of vertebrate formins,
the diaphanous-like formins (mDia1, mDia2, mDia3), FRL formins, and
DAAM formins, each contain well-deﬁned N-terminal regions capable
of binding to Rho GTPases [25] (formin domain structures are
summarized in Fig. 1). We will discuss below how the DRFs are not
only regulated by Rho activation, but also participate in feedback
circuits that modulate Rho GTPase activity.
2.1. Formins are both effectors and modulators of Rho GTPase signaling
TheDRFs contain anN-terminal RhoGTPase binding domain (GBD)
which, upon binding to a Rho family GTPase, alleviates autoinhibition
of the inactive DRF [26]. Rho binding to the GBD results in the
dissociation of the bound N-terminal diaphanous inhibitory domain
(DID) from the C-terminal diaphanous autoregulatory domain (DAD).
Thus, the simplest explanation for the relief of autoinhibition is thatownstream of activation of a G-protein coupled lysophosphatidic acid (LPA) receptor is
r GTP by Rho family GTPase proteins. These then activate DRFs (mDia, FRL, DAAM) and
ed circles), such as stress ﬁbers formed by FHOD1 or mDia. Rho concomitantly activates
n of myosin crossbridges into actin stress ﬁbers. Also shown are active Rho associating
ation adjacent to the endosome, thereby affecting endosome motility. Src cycles to the
y through Src, affects focal adhesion turnover, an event whichmay also affect stress ﬁber
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domain, FH2. Release from autoinhibition allows the FH2 domain to
function in the direct regulation of actin polymerization. Support for
this model is provided by structural analysis of the complex of the
mDia1 N-terminus with RhoA and with DAD which suggest that the
binding of DAD or RhoA is mutually exclusive [27,28]. However, the
recently solved structure of the DAAM1 FH2 domain and studies of
FRL2 and FRL3 autoregulation indicate that inhibitionmediated by the
N-terminal to C-terminal regulatory interactionmay bemore complex
[29,30]. Nevertheless, it is clear that Rho binding is important to the
activation of those DRFs which exhibit autoinhibition.
A consistent effect of Rho activation of the DRFs is the stimulation
of actin ﬁlament formation. This involves a direct role for the FH2
domain in actin ﬁlament assembly. The FH2 domain of mDia1, mDia2,
FRL1, and DAAM1 are all known to be able to directly nucleate actin
ﬁlament polymerization [7,29,31–34]. Along with mDia1 activation
by RhoA, the additional activation of Rho-associated kinase (ROCK)
results in the formation of thick actomyosin stress ﬁbers (Fig. 2) [5].
The particular actin-based structures formed by mDia1 or mDia2
likely depends on the activating GTPase and the concomitant
activation of other downstream effectors as, depending on the
context, several types of actin structures are reported to be generated
by these proteins [35–40]. The binding of various Rho GTPases to
formins and the biological function of these formins is shown in
Table 1.
The speciﬁcity of Rho GTPase-induced activation of mDia1 and
mDia2 has been elaborated on in the speciﬁc context of endosome
trafﬁcking. Both RhoB and RhoD GTPases localize to the membranes of
endosomes, and stimulate DRF activation [41–43]. RhoD is associated
with early endosome motility [44], and Rho B is associated with both
early and late endosome motility [42,43,45]. RhoD acts through the
DRF hDia2C (mDia3 ortholog) to associate early endosomeswith actin
ﬁlaments [41]. This serves to inhibit endosome motility. Similarly,
RhoB induces the association of endosomes with actin ﬁlaments, and
impedes their motility [42]. Either mDia1 [42] or mDia2 [43] can act
downstream of endosome-associated RhoB activation. Each of these
studies, as well as an earlier study by Tominaga et al. [8], has indicated
that the DRF-stimulated actin ﬁlaments associated with endosomes
serve to impede endosome motility, though Wallar et al. [43] alsoTable 1
Rho GTPase associations and ability to affect SRF activation of the animal formins.1
Formin Associated Rho GTPase(s) SRF activation
D. melanogaster
Diaphanous Rho1 Induces MAL-D nuclear translocatio
Cappucino Rho1 n.d.
DAAM RhoA n.d.
X. laevis
DAAM1 RhoA n.d.
M. musculus
FRL1 Rac1 (GTP-independent), CDC42 n.d. (yes for FRL2 and FRL3)
mDia1 RhoA,B,C yes
mDia2 RhoA, B, Cdc42, Rif Yes
mDia3 RhoA, Cdc42, Rac1 n.d.
H. sapiens
hDia1 RhoA n.d.
hDia2C (mDia3) RhoD n.d.
FHOD1 (FHOS) Rac1 Yes
DAAM1 RhoA, B, C, Cdc42⁎⁎a n.d.
n.d. = not done.
1The formins listed are only those known to associate with small GTPases, i.e. those with a
a Cdc42 may bind only weakly to DAAM1, and is reported to not bind in [34].provide evidence that F-actin is required for endosomemovement (as
has a recent report on FGF receptor trafﬁcking through endosomes
[46]). Interestingly, the Rho stimulated mDia induction of actin
ﬁlament association around endosomes, and subsequent decrease in
endosome motility, is dependent upon signaling through Src [8,41].
The role of Src in formin function will be discussed in more detail in
the next section.
The DRF FRL1 has also been reported to function downstream of
multiple Rho family GTPases. This protein was originally described as
a Rac effector required for lamellipodia formation in macrophages
[47]. Surprisingly, FRL1-induced lamellipodia formation was not FH2-
dependent, but instead was dependent on the N-terminal FH3
domain. It should also be noted that the binding of the FRL1 N-
terminus to Rac was not selective for the GTP-bound form of the
GTPase. Thus the relevance of FRL1 as a bona ﬁde Rac effector should
be questioned. Indeed, a more recent study has demonstrated that
FRL1 is most likely a Cdc42 effector required for phagocytic cup
formation in macrophages [7]. FRL1 was found to be preferentially
relieved from its autoinhibited state by GTP-bound Cdc42 and
activation by Cdc42 was shown to stimulate FRL1 membrane
localization. Although FRL1 is likely not activated by Rac, it will be
of interest to investigate the consequences of the FRL1/Rac interac-
tion for Rac activation and subcellular localization as well as the
ability of FRL1 to mediate cross-talk between Cdc42 and Rac signaling
pathways.
The role of GTPase binding in the regulation of the DRF DAAM1 is
also controversial. DAAM1 contains an N-terminal Rho-binding
domain (RBD) and is inhibited by an autoregulatory DID/DAD
interaction [48,49]. However, it is thought that release of DAAM1
autoinhibition is induced not by the interaction of Rho-GTP with the
N-terminal RBD, but rather by the association of the Wnt signaling
protein disheveled with the C-terminal DAD [49]. Consistent with this,
DAAM1 was originally isolated as an effector in a Wnt/frizzled
signaling pathway that stimulates RhoA activation during Xenopus
embryogenesis [50]. In this pathway, activation of the frizzled receptor
allows disheveled to subsequently bind and activate DAAM1. In
support of this hypothesis, expression of a constitutively active
derivative of the DAAM1 C-terminus was reported to induce RhoA
activation and actin stress ﬁber formation in HeLa cells [50].Cellular/biological role References
n Cell motility; mitochondrial motility; hemocyte activation;
membrane invagination
[54,103,123,124]
Cytoplasmic streaming in oocytes and cell polarity [125,126]
Tracheal development [51]
Cell polarity and motility [49,50]
F-actin organization and phagocytsis in macrophages [7,30,47]
Stress ﬁber formation, endosome motility,
mitochondrial motility, adherens junction stability,
axon elongation, microtubule stabilization,
cell motility, cell cycle control, phagocytosis
[5,8,11,123,127–131]
Filopodia information [8,32,35,43,132]
Microtubule attachment to kinetochores [133]
Adherens junction stability [134]
Endosome motility [41]
Lamellapodia and stress ﬁber formation [57,59,60]
F-actin regulation in immune cells [34,48]
GTPase binding domain.
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of RhoA in Cos7 cells [48]. Rather, in this system, both RhoA and Cdc42
were observed to act upstream of DAAM1 and induce its activation.
Activation of DAAM1 by RhoA has also been observed in vitro [34].
Though the FH2-containing DAAM1 C-terminus was originally
proposed to induce actin stress ﬁber formation through Rho activation
[50], subsequent data concerning the function of FH2 domains
indicates that DAAM1 is just as likely to induce stress ﬁber formation
directly. Indeed, inactivating mutations of the DAAM1 FH2 domain
abolish the ability of the DAAM1 C-terminus to induce stress ﬁber
formation [49].
Studies of DAAM function during development of the larval
tracheal system in Drosophila, also support a role for DAAM as a
downstream effector of RhoA [51]. Thus, it is possible that DAAM
normally acts downstream of both RhoA and Wnt signaling. Though
DAAM proteins clearly have the ability to interact with RhoA, it would
be of interest to investigate whether or not Wnt-induced activation of
RhoA by DAAM1 may be inhibited by blocking possible subsequent
interactions between DAAM1 and Rho GEFs (Fig. 3).
In the same study describing the DAAM1-induced activation of
RhoA, it was also shown that a constitutively active (CA) derivative of
mDia2 could activate RhoA [50]. More recently, similar results have
been obtained with mDia1, mDia2, and mDia3 in HEK293 cells [52].
The FH2 domain of mDia1 was sufﬁcient to induce RhoA activation
and was found to bind speciﬁcally to the Rho-GEF LARG, but not the
related proteins p115RhoGEF and PDZ-RhoGEF [52]. This functional
speciﬁcity suggests that the ability of DRFs to induce GTPase activation
will be dependent upon the identity of the endogenous Rho-GEFs
expressed in a speciﬁc cell-type. The ability of DRFs to act in this type
of positive feedback loopmight prove to be a general property of these
proteins, as a functional relationship between DRhoGEF2 and
Diaphanous during Drosophila embryogenesis has also been reported
[53,54].
In mammalian cells, the mDia1-LARG pathway was demonstrated
to regulate orientation of the microtubule organizing center, reﬂective
of an integration of microtubule organization and DRF function [55].
How formins are integratedwithmicrotubule organization is an active
area of research which is reviewed elsewhere in this issue. Interest-
ingly, LARG itself also binds microtubules suggesting a possible
microtubule-based targeting of LARG to the plasma membrane
where RhoA activation would occur. Just such a mechanism has
been proposed to target RhoGEF2 to the membrane in Drosophila. In
cultured Drosophila cells, RhoGEF2 binds the microtubule plus-endFig. 3.DAAM signaling. DAAM1 is activated downstream of both RhoA activation andWnt stim
an interactionwith its C-terminal end. RhoA activates through interactionwith the N-termina
a Rho GEF protein. DAAM1 activation, as with other DRFs, stimulates stress ﬁber formationbinding protein EB1 and Gα12/13 signaling releases this association
(reviewed in [56]). Proper targeting of RhoGEF2 to themembranemay
therefore involve microtubule plus-end searching of the cytoplasm,
with Gα12/13 inducing RhoGEF2 release at the membrane. It remains
to be determined what role Diaphanous may play in this process.
The N-terminus of the formin FHOD1 does not contain any obvious
regions of homology to the GBD of other DRFs [57]. Nonetheless, this
protein is reported to bind Rac through a region immediately N-
terminal to its FH1 domain [58]. As with the DRFs, FHOD1 is inhibited
by an N-terminal to C-terminal DID/DAD autoregulatory interaction
[57,59–61]. On this basis it was proposed that FHOD1 is activated
downstream of Rac1 [59]. However, the interaction of the FHOD1 N-
terminus with Rac is quite weak and occurs whether Rac1 is GTP-
bound or not (or even bound to any nucleotide at all) [59]. Therefore it
is doubtful that Rac1 binding is able to activate FHOD1. However,
FHOD1 has recently been shown to be activated downstream of RhoA
by the ROCK-induced phosphorylation of the FHOD1 DAD [62]. This
phosphorylation results in FHOD1 activation by inhibiting the
interaction of its N-terminal and C-terminal regulatory domains
[62]. This might help explain the previous ﬁnding that FHOD1-
induced stress ﬁber formation is supposedly downstream of Rac
activation, but RhoA-dependent [57]. Perhaps in these circumstances
RhoA acts through ROCK to activate FHOD1, which then associates
with Rac to inhibit lamellipodia formation [57]. This would also ﬁt
with earlier ﬁndings which indicated that the primary role of Rac is to
induce the formation of F-actin rich lamellipodia, with Rac-induced
stress ﬁber formation being dependent upon RhoA activity [17].
3. The Src connection
The ability of SH3 domains to interact with proline-rich sequences,
including the FH1 domain of the limb deformity gene product formin1,
was ﬁrst demonstrated in a study from David Baltimore's laboratory
[63]. In screens for formin binding proteins, the SH3 domains of Abl
and Fyn were subsequently conﬁrmed to bind to the FH1 domain of
formin1 [9,64]. The SH3 domain of c-Src (though not n-Src) was also
shown to mediate the interaction of Src with formin1 at the plasma
membrane [9]. The interaction with Src ascribed a role for formin1 in
signaling at the plasma membrane. Since then, several studies have
placed the DRFs upstream of Src in a number of signaling pathways
[8,41,48,65,66].
A ﬁrst study connecting Rho-activated formin function and Src,
showed that blocking Src function impairs mDia2- and ROCK-inducedulation. Stimulation byWnt acting through disheveled (Dsh) activates DAAM1 through
l GBD of DAAM1. DAAM1 can subsequently activate RhoA, potentially indirectly through
. MLCP — myosin light chain phosphatase. See the text for more details.
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activation in the regulation of actin dynamics, though the FH2 domain
of mDia2 has since been found to be sufﬁcient to nucleate actin
ﬁlaments directly both in vivo and in vitro [32,67]. Nonetheless,
several subsequent studies have been in agreement that Src does
indeed act downstream, or in parallel, of DRF activation
[36,41,51,65,68,69]. Curiously, Src function is not necessary in the
case of FHOD1-induced stress ﬁber formation, though FHOD1-induced
SRF activation, a downstream response to actin polymerization, is
affected [66]. The dependence of DRFs on Src activity to mediate
proper reorganization of the actin cytoskeleton raises the perplexing
question of how the Src kinase protein acts downstream of a direct
nucleator of actin ﬁlament assembly.
One putative role for Src downstream of DRFs in stress ﬁber
formation may be the regulation of focal adhesion turnover. Src is
already well-established as being important for normal focal adhesion
turnover [70,71]. It was found that, in C6 glioma cells, mDia1 is
required to regulate the localization of active c-Src to focal adhesions
[36]. Interference with c-Src function in these cells lead to an
impairment of cell migration because of defective focal adhesion
turnover. It is therefore possible that in the absence of c-Src, stress
ﬁber formation is impaired due to the cell's inability to form new sites
for the attachment of stress ﬁber ends.
The mDia interacting protein (DIP) also links Src to DRF function.
DIP was ﬁrst identiﬁed as an mDia2-interacting protein that affects
v-Src activity [65]. DIP was also found to interact with the focal
adhesion protein Grb2. Accordingly co-expression of DIP and v-Src
lead to altered focal adhesion morphology and expression of mutant
DIP blocked stress ﬁber formation [65]. A subsequent study demon-
strated that DIP is phosphorylated by Src downstream of mDia
activation [68]. The phosphorylation of DIP was found to be necessary
for Src-dependent phosphorylation of p190RhoGAP and Vav2 (a Rac
GEF). The phosphorylation of p190RhoGAP and Vav2, and the resulting
inhibition of RhoA and activation of Rac1, also provides another
example of formin-induced feedback regulation of Rho GTPases (see
above). mDia-mediated RhoA inhibition and Rac activation was
similarly reported in an earlier study [72]. This feedback may help to
achieve balanced levels of Rho family GTPase activation that may be
required for the proper regulation of focal adhesion turnover.
It is not clear how the effects of Src on focal adhesion turnover and
DRF-induced stress ﬁber formation are connected to its effects on
DRF-regulated endosome motility. The actin ﬁlaments formed on and
adjacent to endosomes [41–43] are presumably not tethered to focal
adhesion proteins. Interestingly, a recent study investigating Src-
family kinase trafﬁcking has demonstrated that c-Src moves primarily
between the plasma membrane and late endosomes/lysosomes in
living cells [70]. This is consistent with a model where Src activity is
required for DRF function at both plasma and endosomal membranes.
In this case, perhaps analogous Src targets exist on endosomes and at
focal adhesions to connect them to the actin cytoskeleton, thus
explaining the reliance of mDia on Src activity in regulating endosome
motility. The role of Src in formin-induced activation of MAL/SRF-
dependent transcription [8,66] is discussed below.
4. Formin signaling to the nucleus
As already discussed, formins plays a direct role in regulating
dynamics of the actin cytoskeleton and microtubule network.
However, studies of the original ld mutations of formin1 suggested
that formins might also have a nuclear function [73] and a number
of formins have been shown to have functional nuclear localization
signals [73–76]. Despite this, a requirement for formin function in
the nucleus has, for the most part, still not been clearly
demonstrated. Better understood is the ability of formin-induced
actin polymerization to activate the actin/MAL/SRF transcriptional
response [8,11,14,32,77,78].Serum Response Factor (SRF) is a ubiquitously expressed MADS-
box containing transcription factor. SRF −/− mice fail to gastrulate
and die during early embryogenesis [79]. SRF-null ES cells can
proliferate, but exhibit defects in cell adhesion and their actin
cytoskeleton due to reduced expression of cytoskeletal and focal
adhesion proteins such as actin, vinculin, talin and zyxin [77,80].
Expression of this subset of SRF target genes occurs in response to
depletion of the cellular pool of monomeric G-actin [10–13,81–85].
Actin-regulated activation of SRF target genes is mediated by the
ubiquitously expressed myocardin-related SRF co-factors MAL22 (a.k.
a. MRTF-A and MKL1) and MAL16 (a.k.a. MRTF-B and MKL2) [84–89].
In most tissues, both MAL proteins are expressed and functionally
interchangeable with regards to activation of SRF-dependent tran-
scription [84,87,90]. However, recent studies in knockout mice
suggest that there is a speciﬁc requirement for MAL22 during
development of the breast myoepithelum [91] and a speciﬁc
requirement for MAL16 in formation of the branchial arch arteries
[92]. As with SRF-null cells, loss of MAL activity leads to defects in cell
adhesion and morphology [88,93]. Consistent with this observation,
of the one hundred sixty known SRF target genes, twenty-nine
encode cytoskeletal or contractile proteins and microarray analysis
shows that at least six of these genes are down-regulated in
ﬁbroblasts expressing dominant negative MAL [88].
Transcriptional activation by MAL is regulated by its three N-
terminal RPEL motifs. The regulatory RPEL repeats bind directly to G-
actin and mediate the G-actin-induced repression of the actin/MAL/
SRF pathway [82,84,94]. N-terminal deletion derivatives of MAL that
lack the RPEL motifs are localized to the nucleus and are constitu-
tively active [84]. The direct regulation of the expression of many
cytoskeletal components by MAL, in response to changes in actin
dynamics, has led to the proposal that the actin/MAL/SRF pathway is
a central regulator of cell morphology [95]. Indeed, conditional
deletion of SRF suggests that this pathway is required in mice for
neuronal cell migration and axon outgrowth, myogenesis, and
assembly of the contractile apparatus in skeletal, cardiac and smooth
muscle cells [79,80,96–102]. Similarly, in Drosophila the MAL/SRF
pathway is also required in vivo for border cell migration, elaboration
of the larval tracheal system, and formation of intervein tissue in the
wing [103–105].
A number of studies have shown that over-expression of consti-
tutively active formin derivatives is sufﬁcient to induce activation of
MAL/SRF-dependent transcription [8,10–14,32,78,84,103,106,107]
(formins capable of inducing SRF activity are summarized in Table
1). The regulation of this pathway is perhaps best understood in the
context of MAL/SRF activation induced by serum stimulation of
quiescent ﬁbroblasts, although a similar pathway also operates in
C2C12myoblasts and smoothmuscle cells [10–13,32,82–84,94,107–111].
In ﬁbroblasts, activation is entirely RhoA dependent [10,81,84] with the
effects of RhoA being mediated by activation of mDia1 [8,10,11,32]
(mDia2 is not expressed in these cells). CA derivatives of mDia1 are
sufﬁcient to induce potent activation of a MAL/SRF reporter gene in a
Rho-independent manner [8,10,11]. This point is crucial; CA derivatives
of ROCK and other Rho effectors are able to induce MAL/SRF activation,
however, this activation remains Rho-dependent [13,112]. Thus, mDia1
is a primary Rho effector that is sufﬁcient to induce directly the
activation of MAL/SRF dependent transcription. Consistent with this
model, over-expression of a dominant negative (DN) monomeric
derivative of the FH2 domain of mDia1 is able to inhibit serum-induced
MAL/SRF activation. This construct also inhibits activation induced by
co-expression of CA mutants of RhoA, mDia1, mDia2, ROCK and VASP
[11–13,32,107]. It should be noted, however, that the DN mDia1 FH2
derivative is thought to act as a barbed-end F-actin capping protein
[32,113] and may therefore have a pleiotropic inhibitory effect on actin
polymerization. That said, the requirement for mDia1 downstream of
RhoA has also been demonstrated using a DNderivative of themDia1N-
terminus that works in trans to recapitulate the DID/DAD mediated
188 K.G. Young, J.W. Copeland / Biochimica et Biophysica Acta 1803 (2010) 183–190autoinhibition of mDia1 [75]. In addition, siRNA-mediated knockdown
of mDia1 expression has also shown that it is required for Rho-
dependent MAL/SRF activation in C2C12 myoblasts [110].
MAL/SRF-dependent transcription, as noted above, is regulated by
the direct interaction of monomeric G-actin with the RPEL motifs of
MAL (Fig. 4) [82–84,94]. In accordance with this observation,
activation of the pathway by mDia1 is absolutely dependent upon
FH2 activity. This domain is both necessary and sufﬁcient for MAL/SRF
activation; deletions or point mutations in the FH2 domains of mDia1
or mDia2 that abolish FH2-induced actin polymerization in vitro also
abolish their ability to activate MAL/SRF-dependent transcription in
vivo [11,32]. Conversely, activation of MAL/SRF by CA mDia1
derivatives is inhibited by co-expression of a non-polymerizable
mutant β-actin suggesting that mDia1-induced depletion of G-actin is
absolutely necessary for MAL activation [11].
CA derivatives of mDia1 and mDia2 induce an incredibly robust
activation of the MAL/SRF pathway, which is matched only by over-
expression of CA derivatives of MAL itself [84,107]. However, the
ability to induce robust activation of MAL/SRF is not unique to mDia1
or mDia2. Indeed, CA derivatives of the FH2 domains of DAAM1,
DAAM2, FRL2, FRL3, INF1 and INF2 are able to induce activation of this
pathway to a similar extent as mDia1 and mDia2 [30,114] (J.C.
unpublished observations), while Formin1, FHOD1 and FHOD3-
induced activation is to a lower level [14,32,106] (J.C. unpublished
observations). It is not clear if the relative ability of formins to activate
MAL/SRF correlates with the relative ability of these proteins to
induce actin polymerization, or with their relative ability to activate
additional factors required for stimulation of the MAL/SRF pathway.
For example, mDia1 has been posited to act through other factors
besides actin polymerization to potentiate MAL/SRF activation [8,78].
In particular, the recruitment of Src kinase by FH1 has been suggested
to be essential for MAL/SRF activation downstream of mDia1, mDia2
and FHOD1 [8,65,66]. Over-expression of the CA Src mutant Y530F isFig. 4. DRF activation of SRF-mediated gene transcription. Formin activation of SRF-depend
translocation of MAL is regulated by a pool of free cytoplasmic G-actin (red circles). As wel
recent study has suggested that nuclear actin may be exported by a proﬁlin (P)-actin-export
cytoskeletal-related genes, such as β-actin, vinculin and different myosin genes. See the texsufﬁcient to activate a MAL/SRF reporter gene [8,11,115] and the DN
Src mutant K298M/Y530F is able to inhibit mDia1- and mDia2-
induced activation of MAL/SRF [8]. However, activation by SrcY530F
is still RhoA-dependent and is inhibited by co-expression of non-
polymerizable actin mutants [11]. There are also conﬂicting reports
regarding the ability of v-src to activate a MAL/SRF reporter gene
[8,115]. In addition, serum-induced activation of MAL/SRF is not
affected by inhibition of Src activity through the expression of C-
terminal Src Kinase expression, the expression of kinase dead
SrcK298M, or the small molecule Src inhibitor PP2 [11]. It is also
difﬁcult to reconcile a direct role for Src downstream of mDia1 or
mDia2 with the ﬁnding that the FH1 domain is not required for MAL/
SRF activation [11,32]. Thus, in terms of activation of the MAL/SRF
pathway, the data is most consistent with a model where Src acts
upstream or in parallel to mDia1. However, Src may still play an
essential role downstream of mDia1 in other processes.
Although many formins contain functional nuclear localization
sequences, it is apparently their ability to regulate actin dynamics in
the cytoplasm that is essential for MAL/SRF activation [11,32,57]. This
does not exclude a potential nuclear function for mDia1 (and perhaps
other proteins) in activating the MAL/SRF pathway. The import of
MAL into the nucleus is regulated by its association with cytoplasmic
G-actin while MAL nuclear export and MAL-induced transcriptional
activation is regulated by G-actin in the nucleus [94]. It is interesting
to note that mDia1 has been found associated with the exportin 6
nuclear export complex that is required for export of proﬁlin-actin
from the nucleus [116]. In this case, stimulation of actin polymeriza-
tion in the cytoplasm by mDia1 would initiate activation of the
pathway, while stimulation of actin export from the nucleus might
assist in potentiating MAL activity in the nucleus.
It has been shown that MAL is able to regulate target gene
activation independently of SRF, through its association with other
transcription factors [117,118]. Given that MAL nuclear translocation isent gene transcription occurs through MAL translocation to the nucleus. The nuclear
l, nuclear actin can inhibit MAL/SRF activation of the serum response element (SRE). A
in 6 (Exp 6) complex that binds to mDia1. SRE sequences reside at the 5′ end of multiple
t for more details.
189K.G. Young, J.W. Copeland / Biochimica et Biophysica Acta 1803 (2010) 183–190governed by its direct association with G-actin [82,84,94], it is likely
that formins will also participate in the activation of SRF-independent
MAL target genes. It has also been suggested that mDia1 regulates
MyoD expression in C2C12 myoblasts through both SRF-dependent
and independent pathways [110].
Recent studies suggest that, in addition to MAL/SRF activation,
formins are able to regulate transcription through other pathways.
Caspase cleavage of FHOD1 during apoptosis results in the unmasking
of its N- and C-terminal nuclear localization signals. In apoptotic cells,
the C-terminal fragment is efﬁciently targeted to nucleoli where it
participates in the repression of RNA polymerase I transcription [119].
Fozi-1 is a unique FH2-containing, Zn-ﬁnger transcription factor that
is expressed in the gustatory neurons and body wall muscle cells of C.
elegans [74,120]. The Fozi-1 FH2 domain has apparently lost the
ability to regulate actin dynamics, but is still required for full Fozi-1
activity, perhaps due to its ability to form homodimers [74,120].
Finally, it is intriguing to speculate that formins may regulate
transcription through remodeling of the nucleoskeleton. It has been
reported recently that ligand-induced transcriptional activation by
estrogen receptor-α stimulates interchromosomal interactions
between target genes. The activated target genes move to speciﬁc
sites within the nucleus that are thought to be “transcription
factories” [121,122]. This movement is dependent upon nuclear
actin and myosin I and disrupted by actin-binding drugs [122].
Given that formin nuclear localization can be regulated by extra-
cellular signals [73,75,76,119], it is tempting to propose that they may
play some role in this process.
5. Concluding remarks
Great progress has been made over the last ten years in describing
the cellular function of formin homology proteins. It is clear, however,
that much remains to be resolved in deciphering their precise roles
within various cytoskeletal remodeling pathways. In particular, the
discovery that the DRFs DAAM1 and mDia1 are able to act both as
activators and effectors of Rho family GTPases will necessitate the re-
assessment of the function of these proteins in many cellular
processes. It will be of interest to determine if activation of Rho
GTPases is a common function of all formins, or unique to this
subfamily. Finally, it is becoming clear that formins play essential roles
in nuclear signaling events and may also participate in governing
nucleoskeletal dynamics.
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